1-amino-3-phenylindazole | 33334-10-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-amino-3-phenylindazole
• 英文别名: 3-phenyl-indazol-1-ylamine；3-Phenylindazol-1-amine
• CAS: 33334-10-0
• 化学式: C₁₃H₁₁N₃
• 分子量: 209.25
• InChiKey: OUEXRPDKOLZLPK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-amino-3-phenylindazole 生成 (E)-1-(4-methoxyphenyl)-N-(3-phenylindazol-1-yl)methanimine
  参考文献：
  名称：

  ADGER B. M.; BRADBURY S.; KEATING M.; REES C. W.; STORR R. C.; WILLIAMS M+, J. CHEM. SOC. PERKIN TRANS. , 1975, PART 1, NO 1, 31-40

  摘要：

  DOI：
• 作为产物：
  描述：

  3-苯基-1H-吲唑 以60%的产率得到
  参考文献：
  名称：

  ADGER B. M.; BRADBURY S.; KEATING M.; REES C. W.; STORR R. C.; WILLIAMS M+, J. CHEM. SOC. PERKIN TRANS. , 1975, PART 1, NO 1, 31-40

  摘要：

  DOI：

文献信息

• [EN] DERIVATIVES OF 1-[(IMIDAZOLIDIN-2-YL)IMINO)]INDAZOLE<br/>[FR] DÉRIVÉS DU 1-[(IMIDAZOLIDIN-2-YL)IMINO)]INDAZOLE
  申请人：IMP INNOVATIONS LTD

  公开号：WO2009071906A1

  公开（公告）日：2009-06-11

  The invention provides a compound of formula (I) wherein R1 denotes hydrogen, methyl or phenyl; R2, R3, R4 and R5 denote hydrogen, halogen, preferably a chlorine atom, alkyl, preferably methyl, alkoxyl, preferably methoxyl; m denotes a number 0 or 1; and HX denotes sulfuric, phosphoric, acetic, malonic, fumaric, oxalic, lactic, tartaric, citric, gluconic, p-toluenesulfonic, methanesulfonic acid, hydrogen bromide or hydrogen iodide, preferably hydrogen chloride. The use of the compounds as α2-adrenergic receptor agonists is also provided.

  本发明提供了一种式子为(I)的化合物，其中R1表示氢、甲基或苯基；R2、R3、R4和R5表示氢、卤素，优选为氯原子，烷基，优选为甲基，烷氧基，优选为甲氧基；m表示数字0或1；HX表示硫酸、磷酸、醋酸、马龙酸、富马酸、草酸、乳酸、酒石酸、柠檬酸、葡萄糖酸、对甲苯磺酸、甲磺酸、氢溴酸或氢碘酸，优选为氢氯酸。本发明还提供将该化合物用作α2肾上腺素受体激动剂的方法。
• 1-[(Imidazolidin-2-yl)imino]indazole. Highly α₂/I₁ Selective Agonist: Synthesis, X-ray Structure, and Biological Activity
  作者：Franciszek Sa̧czewski、Anita Kornicka、Apolonia Rybczyńska、Alan L. Hudson、Shu Sean Miao、Maria Gdaniec、Konrad Boblewski、Artur Lehmann

  DOI：10.1021/jm800112s

  日期：2008.6.1

  Novel benzazole derivatives bearing a (imidazolidin-2-yl)imino moiety at position I or 2 were synthesized by reacting 1-amino- or 2-aminobenzazoles with N,N'-bis(tert-butoxycarbonyl)imidazolidine-2-thione in the presence of HgCl2. Structures of 1-[(imidazolidin-2-yl)imino]indazole (marsanidine, 13a) and free base of the 4-Cl derivative 12e were confirmed by X-ray single crystal structure analysis. Compound 13a was found to be the selective alpha(2)-adrenoceptor ligand with alpha(2)-adrenoceptor/imidazoline I-1 receptor selectivity ratio of 3879, while 1-[(imidazolidin-2-yl)imino]-7-methylindazole (13k) proved to be a mixed alpha(2)-adrenoceptor/imidazoline I-1 receptor agonist with alpha 2/I-1 selectivity ratio of 7.2. Compound 13k when administered intravenously to male Wistar rats induced a dose-dependent decrease in mean arterial blood pressure (ED50 = 0.6 mu g/kg) and heart rate, which was attenuated following pretreatment with alpha(2A)-adrenoceptor antagonist RX821002. Compound 13a may find a variety of medical uses ascribed to alpha(2)-adrenoceptor agonists, and its 7-methyl derivative 13k is a good candidate for development as a centrally acting antihypertensive drug.
• DERIVATIVES OF 1-[(IMIDAZOLIDIN-2-YL)IMINO)]INDAZOLE
  申请人：Imperial Innovations Limited

  公开号：EP2227464A1

  公开（公告）日：2010-09-15
• [EN] INDAZOLE DERIVATIVES AS JNK INHIBITORS<br/>[FR] DERIVES D'INDAZOLE UTILISES COMME INHIBITEURS DE JNK ET COMPOSITIONS ET METHODES ASSOCIEES A CEUX-CI
  申请人：——

  公开号：WO2002010137A9

  公开（公告）日：2003-02-06

  [EN] Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: (I), wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.
  [FR] La présente invention concerne des composés agissant comme des inhibiteurs sélectifs de JNK. Ces composés sont des dérivés d'indazole représentés par la formule (I), dans laquelle R<1>, R<2> et A sont tels que définis ici. Ces composés sont utilisés dans le traitement de toute une série d'états pathologiques sensibles à l'inhibition de JNK. De plus, l'invention concerne des méthodes de traitement de ces états pathologiques, ainsi que des compositions pharmaceutiques contenant un ou plusieurs des composés précités.
• ADGER B. M.; BRADBURY S.; KEATING M.; REES C. W.; STORR R. C.; WILLIAMS M+, J. CHEM. SOC. PERKIN TRANS. <JCPK-BH>, 1975, PART 1, NO 1, 31-40
  作者：ADGER B. M.、 BRADBURY S.、 KEATING M.、 REES C. W.、 STORR R. C.、 WILLIAMS M+

  DOI：——

  日期：——